|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1399 NEW YORK AVENUE NW |
Address2 | SUITE 300 |
| City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
||||||||
| TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Evan L. Morris, Vice President, Government Affairs |
Date | 04/19/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues relating to government purchases and stockpiling of pandemic drugs - Tamiflu
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Anna |
Sagely |
|
|
|
Darin |
Gardner |
|
|
|
Katherine |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1908 Intellectual Property and Process Patent Issues
S. 515 & H.R. 1260 - Patent Reform Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Darin |
Gardner |
|
|
|
Anna |
Sagely |
|
|
|
Katherine |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Implementation of HR1
Medicare Prescription Drug and Modernization Act of 2003
Issues relating to PDUFA, stimulus
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Physician payment disclosure including S.301
Physician Payments Sunshine Act of 2009
H.R. 3962, Affordable health Care for Americans Act
H.R. 3590, Patient Protection and Affordable Care Act
H.R. 4872, the Reconciliation Act of 2010
Follow-on biologics including H.R. 154, the Pathway to Biosimilars Act
S. 726/H.R. 1427, Promoting Innovationo and Access to Life Saving Medicines Act
H.R. 3962, Affordable Health Care for America Act
Comparative effectiveness legislation including S. 1213
Patient-Centered Outcomes Research Act of 2009
H.R. 3200, America's Health Future Act
H.R. 1548 - Pathway for Dissimilar Act
Legislative changes in the health care reform bill regarding dissimilar
Follow-on biolotics provisions in P.L. 111-148 "Patient protection and Affordable Care Act."
Pandemic Preparedness - Tamiflu
Exploring additional funding for antiviral stockpiling in response to H1N1 and H5N1 Pandemic Influenza
H.R. 1105 - omnibus Appropriations Act
FY10 labor HHS Appropriations Legislation
H.R. 1105 - Omnibus Appropriations Act
FY10 Labor HHS Appropriations legislation
H.R. 2346 supplemental Appropriations Act of 2009
FY11 Labor, HHS and Education Appropriates related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment
FY11 State Foreign Operations Appropriations related to USAID and funding for pandemic influenza
H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
Ryan White CARE Act reauthorization
S. 1679, Affordable Health Choices Act
S. 1796, America's Healthy Future Act of 2009
Pharmaceutical import safety legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Labor HHS Appropriations - S. 3230 and H.R. 3042
Homeland Security Appropriations S.3181 and H.R. 6947
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS), Executive Office of the President (EOP), Office of Personnel Management (OPM), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Monitoring proposals on U.S. tax treatment of foreign corporations
S. 506, Stop Tax Haven Abuse Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
` |
|
|
Anna |
Sagely |
|
|
|
Darin |
Gardner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
S. 565/H.R. 1458 - providing extended coverage for immunosuppressive drugs to beneficiaries under ther Medicare Program that have received a kidney transplant
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
|
Darin |
Gardner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Monitor food safety and supply chain issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
|
Darin |
Gardner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Monitor issues related to export rules and regulations
International patent issues
WTO matters and other international trade issues impacting biotech and pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Stephanie |
Dyson |
|
|
|
David |
Burt |
|
|
|
Katherin |
Martin |
|
|
|
Anna |
Sagely |
|
|
|
Darin |
Gardner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |